Proteomics

Dataset Information

0

Functional proteomics-based investigation of the cellular response to farnesyl transferase inhibition in lung cancer (tipifarnib treatment of lung cancer cells)

ABSTRACT: The subcellular localization of proteins can be highly dynamic and regulated by post-translational modifications. Farnesylation is a lipid modification that enables anchoring of proteins to cellular membranes, and thus, spatially resolved signaling and activity. Due to the importance of farnesylation for cellular functions, farnesyltransferase inhibitors (FTIs) including tipifarnib were developed and are being tested in oncology clinical trials. The current lack of knowledge on the functional impact of FTIs on hundreds of farnesylation substrates limits response prediction and their use in cancer precision medicine. Here, we report a global functional proteomics investigation of the impact of tipifarnib in multiple lung cancer cell lines. This dataset includes proteome-wide analysis of the effects of tipifarnib at 6, 12, 24, 48 h timepoints. The data covers experiments in five lung cancer cell lines (NCI-H727, NCI-H1568, NCI-H1975, NCI-H2009 and NCI-H1944).

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

DISEASE(S): Lung Cancer

SUBMITTER: Georgios Mermelekas  

LAB HEAD: Lukas Orre

PROVIDER: PXD050480 | Pride | 2025-05-13

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20220729_GMLOYP1-32_SET1_TOTAL_PROTEOME_IPG37-49_fr01.raw Raw
20220729_GMLOYP1-32_SET1_TOTAL_PROTEOME_IPG37-49_fr02.raw Raw
20220729_GMLOYP1-32_SET1_TOTAL_PROTEOME_IPG37-49_fr03.raw Raw
20220729_GMLOYP1-32_SET1_TOTAL_PROTEOME_IPG37-49_fr04.raw Raw
20220729_GMLOYP1-32_SET1_TOTAL_PROTEOME_IPG37-49_fr05.raw Raw
Items per page:
1 - 5 of 393
altmetric image

Publications

Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer.

Pan Yanbo Y   Berkovska Olena O   Marathe Soumitra S   Mermelekas Georgios G   Gudoityte Greta G   Wolide Amare D AD   Arslan Taner T   Seashore-Ludlow Brinton B   Lehtiö Janne J   Orre Lukas M LM  

iScience 20250121 2

Farnesylation is a lipid post-translational modification of proteins crucial for protein membrane anchoring and cellular signaling. Farnesyltransferase inhibitors (FTIs), such as tipifarnib, are being tested in cancer therapy. However, the full impact of FTIs on farnesylation substrates remains poorly understood, thus limiting their use in precision medicine. In this study, we performed a global proteomics analysis to investigate farnesylation and the effects of tipifarnib in lung cancer cell li  ...[more]

Similar Datasets

Proteomics : Functional proteomics-based investigation of the cellular response to farnesyl transferase inhibition in lung cancer (PTP4A1 silencing and IFN treatment of NCI-H1944 cells)
2025-05-13 | PXD050446 | Pride
Proteomics Immediate adaption – Quantitative Proteomics of BCL6 silencing and EGFR TK inhibition
2020-12-09 | PXD016605 | Pride
Proteomics Proteomic profiling in fibrolamellar carcinoma patient tumor tissue
2025-05-06 | PXD051527 | Pride
Proteomics Proteome profiling of whole plasma and plasma-derived extracellular vesicles facilitates the detection of tissue biomarkers in the non-obese diabetic (NOD) mouse
2022-10-20 | PXD033867 | Pride
Proteomics Functional proteomics-based investigation of the cellular response to farnesyl transferase inhibition in lung cancer (farnesylated proteins pull-down)
2025-04-09 | PXD050725 | Pride
Proteomics Investigating the target and off-target landscape of PLK1 small molecule inhibitor volasertib
2021-08-23 | PXD024040 | Pride
Proteomics Human Lung cancer proteomics and proteogenomics LC/MS&MS
2021-12-15 | PXD020191 | Pride
Proteomics,Multiomics HiRIEFII proteomics and proteogenomics of A431 cells and five histologically normal tissues
2018-01-19 | PXD006291 | Pride
Proteomics HiRIEF-LC-MS based proteomics analysis of subcellular fractions of human CD4+ T-Cells with and without T-cell Receptor stimulation.
2019-11-13 | PXD013284 | Pride
Proteomics U2OS LC MSMS upon siRNA-eIF4A3 or 5nM ActD treatment.
2021-09-08 | PXD016005 | Pride